CMS Medicare Drug Cost Survey Extension and 340B Implications
Key Questions
What is the CMS extension for the Medicare drug cost survey?
CMS extended the deadline for hospitals to complete the Medicare drug cost survey, which has significant implications for 340B programs. FQHCs as covered entities should monitor closely.
How does the drug cost survey impact 340B programs?
The survey increases scrutiny on 340B reimbursements and compliance amid HHS cuts and House blocks. It threatens pharmacy and 340B profits from IRA-negotiated drugs via list price reductions.
What risks do FQHCs face with 340B amid national scrutiny?
FQHCs must watch reimbursement and compliance risks as covered entities. National oversight grows with survey extensions and policy blocks.
CMS extends deadline for hospitals' Medicare drug cost survey with significant 340B scrutiny/HHS cuts; FQHCs as covered entities monitor reimbursement/compliance risks amid House blocks and national watch.
Sources (2)
Updated Apr 9, 2026